¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • protective antibody
    ¹æ¾îÇ×ü
  • radioimmunoprecipitating antibody
    ¹æ»ç¸é¿ªÄ§ÀüÇ×ü
  • reaginic antibody
    Áï½ÃÇü°ú¹ÎÇ×ü
  • secretory antibody
    ºÐºñÇ×ü
  • sensitizing antibody
    ¹Î°¨È­Ç×ü
  • univalent antibody
    Àϰ¡Ç×ü
  • warm antibody
    ¿Â³­Ç×ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • percent reactive antibody test
    ¹éºÐÀ²¹ÝÀÀÇ×ü°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • antibody-mediated immunity
    Ç×ü¸Å°³ ¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • indirect fluorescent antibody technique
    °£Á¢Çü±¤Ç×ü¹ý
  • indirect immunofluorescence antibody
    °£Á¢¸é¿ªÇü±¤Ç×ü
  • inhibiting antibody
    ¾ïÁ¦Ç×ü.
  • instructive theory of antibody production
    Áö·É¼³ (Ç×ü»ý»ê)
  • platelet antibody
    Ç÷¼ÒÆÇÇ×ü(¡­ù÷ô÷).
  • polivalent antibody
    ´Ù°¡Ç×ü(Òýʤù÷ô÷).
  • polyclonal antibody
    ´ÙŬ·ÐÇ×ü
  • polyclonal antibody
    ´ÙŬ·Ð¼º Ç×ü
  • polyclonal antibody
    ´Ù¼¼Æ÷±ºÇ×ü, ¿©·¯¹«¸®Ç×ü
  • polyvalent antibody =multivalent a.
    ´Ù°¡Ç×ü(¡­ù÷ô÷).
  • polyvalent antibody =multivalent a.
    ´Ù°¡Ç×ü(Òýʤù÷ô÷)
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • protective antibody
    ¹æ¾îÇ×ü(¡­ÛÁåÝù÷ô÷).
  • radioimmunoprecipitating antibody
    ¹æ»ç¸é¿ªÄ§°­¼º Ç×ü.
  • reaginic antibody
    ¸®¾ÆÁøÇ×ü(¡­ù÷ô÷).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • antibody-mediated immunity
    Ç×ü¸Å°³ ¸é¿ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü.
  • cytotoxic antibody
    °ú¼¼Æ÷µ¶Ç×ü, ¼¼Æ÷µ¶¼ºÇ×ü.
  • cytotoxic antitumor antibody
    ¼¼Æ÷µ¶¼ºÇ×Á¾¾çÇ×ü
  • cytotropic antibody
    ¼¼Æ÷ģȭ¼ºÇ×ü.
  • deficient syndrome, antibody
    Ç×ü°áÇÌÁõÈıº
  • diagnostic antibody
    Áø´Ü¿ë Ç×ü.
  • direct fluorescent antibody
    Á÷Á¢¸é¿ªÇ×ü
  • direct fluorescent antibody staining
    Á÷Á¢Çü±¤Ç×ü¿°»ö
  • divalent antibody
    À̰¡Ç×ü.
  • donath-landsteiner antibody
    donath-landsteiner Ç×ü
  • donath-landsteiner antibody
    Donath-Landsteiner antibody
  • double layer fluorescent antibody technique
    ÀÌÃþÇü±¤Ç×ü¹ý.
  • enzyme antibody technique
    È¿¼ÒÇ×ü¹ý.
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü.
  • enzyme-antibody conjugate
    È¿¼Ò-Ç×ü ¹èÇÕü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
FTA-ABS test Fluorescent Treponemal Antibody ABSorption test
ICA   1) Islet Cell Antibody
  2) Internal Carotid Artery
IFA Immuno-Fluorescence Antibody Test(= Assay)
IFA test Indirect Fluorescent Antibody test
IgM¥áHBc IgM Antibody against Hepatitis B core Antigen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
anti HAV Antibody to hepatitis A virus
anti HBc Antibody to hepatitis B core antigen
anti-HBe Antibody to hepatitis B e antigen
anti HBs Antibody to hepatitis B surface antigen
ACB Antibody-coated bacteria
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
treponema-immobilizing antibody Antibody, evoked during syphilitic infections, possessing specific affinity for Treponema pallidum, and which in the presence of complement immobilises the organism.
Synonym: immobilizing antibody, treponemal antibody.
(05 Mar 2000)
treponemal antibody Antibody, evoked during syphilitic infections, possessing specific affinity for Treponema pallidum, and which in the presence of complement immobilises the organism.
Synonym: immobilizing antibody, treponemal antibody.
(05 Mar 2000)
univalent antibody An "incomplete" form of antibody that may coat antigen, but which according to the "lattice theory" does not have a second receptor for attachment to another molecule of antigen; in the case of Rh+ erythrocytes, such an anti-Rh antibody may coat the cells but not cause them to agglutinate in saline; however, agglutination does occur when such coated cells are suspended in serum or other protein media, such as albumin, therefore called serum agglutinin.
Synonym: incomplete antibody, inhibiting antibody.
(05 Mar 2000)
fluorescein-conjugated antibody Refers to an antibody that has joined with a fluorescein molecule.
(09 Oct 1997)
fluorescent antibody Immunoglobulin molecule which as been coupled with a fluorescent molecule so that it exhibits fluorescence.
(09 Oct 1997)
fluorescent antibody technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (fluorescent antibody technique, direct) or an indirect method, by formation of antigen-antibody complex which is then labelled with fluorescein-conjugated anti-immunoglobulin antibody (fluorescent antibody technique, indirect). The tissue is then examined by fluorescence microscopy.
(12 Dec 1998)
fluorescent antibody technique, direct A form of fluorescent antibody technique utilizing a fluorochrome conjugated to an antibody, which is added directly to a tissue or cell suspension for the detection of a specific antigen.
(12 Dec 1998)
fluorescent antibody technique, indirect A form of fluorescent antibody technique commonly used to detect serum antibodies and immune complexes in tissues and microorganisms in specimens from patients with infectious diseases. The technique involves formation of an antigen-antibody complex which is labelled with fluorescein-conjugated anti-immunoglobulin antibody.
(12 Dec 1998)
fluorescent antibody techniques Lab techniques for locating antigens in a prepared tissue sample by using antibodies with fluorescent labels which will bind to the antigens of interest.
(09 Oct 1997)
fluorescent antibody titre An indirect method of measuring the concentration of an antibody in serum through the detection of fluorescent light emitted in a chemical reaction.
(27 Sep 1997)
fluorescent antinuclear antibody test FANA test, a test for antinuclear antibody components; used, in particular, for the diagnosis of collagen-vascular diseases.
(05 Mar 2000)
fluorescent treponemal antibody-absorption test <investigation> A sensitive and specific serologic test for syphilis. It is more specific than the VDRL assay.
The patient's serum is diluted to remove non-specific antibodies and then mixed on a glass slide with Nichol's strain of Treponema pallidum. If antibodies are present in the patient's serum they bind to the antigen and the bound antibodies are detected with fluoresceinated antihuman gamma-globulin antibody.
Synonym: FTA-ABS test.
(12 Sep2002)
Forssman antibody A heterogenetic antibody specific for the Forssman group of heterogenetic antigens.
Synonym: heterophil antibody, heterophile antibody.
(05 Mar 2000)
Forssman antigen-antibody reaction The combination of Forssman antibody with heterogenetic antigen of the Forssman type, as in the agglutination of sheep erythrocytes (which contain Forssman antigen) by serum from a person with infectious mononucleosis which contains Forssman antibody.
Synonym: Forssman reaction.
(05 Mar 2000)
lyme disease antibody A blood test which measures for the presence of Lyme disease antibodies. A nonreactive or serum titre of less than 1:256 is normal. A rising titre over time is more diagnostic. False positives due occur in those with rheumatoid arthritis and lupus.
(27 Sep 1997)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
antibody e. see prozone.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
antibody h. a measure of the mean survival time of antibody molecules following their formation, usually expressed as the time required to eliminate 50 per cent of a known quantity of immunoglobulin from the animal body. Half-life varies from one immunoglobulin class to another.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
antibody i. deficiency in immunity mediated by B lymphocytes, marked by hypo- or dysgammaglobulinemia and recurrent bacterial otitis media and sinopulmonary infections. For a list of disorders of this type, see table.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
antibody s. a method of determining the presence and amount of anti-HLA antibodies in the serum of a potential allograft recipient: aliquots of the recipient's serum are mixed with a panel of leukocytes from well-characterized cell donors and complement is added. Reaction between the recipient's pre-existing antibody and specific antigen in the donor cells leads to cell lysis; the percentage of different cells lysed provides a rough measure of the sensitization of the recipient (referred to as the panel reactive antibody).
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
antibody-dependent cell-mediated c. lysis of target cells coated with antibody by effector cells with cytolytic activity and Fc receptors, including K cells, macrophages, and granulocytes; a form of type II hypersensitivity reaction. ADCC involves binding of the effector cell by means of Fc receptors which bind to the Fc portion of the IgG molecule. Lysis of the target cell is extracellular, requires direct cell-to-cell contact, and does not involve complement.
Ãâó: www.mercksource.com/pp/us/cns/cns_health_library.j...
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á